Biblio Discovery — Demo Discovery Service

53 results for "Massimo Franchini"

Showing 1–20 · 0.57 seconds · RSS

  1. Journal Article

    Polycythemia vera and management of the thrombotic risk: an update

    Massimo Franchini

    Bleeding, Thrombosis and Vascular Biology, Vol. 2 No. 4 · 2023 · English · DOAJ Scopus

    Polycythemia vera (PV) is a chronic Philadelphia-negative myeloproliferative neoplasm caused by JAK2 mutation and characterized predominantly by the overproduction of red blood cells. The current treatment strategies of PV are based on periodic phlebotomies aimed at preventing thrombotic events…

  2. Journal Article Full text

    Antibodies and SARS-CoV-2: New Data on Diagnostics and Therapeutics

    Daniele Focosi; Massimo Franchini

    Life, Vol. 12 No. 5 · 2022 · English · DOAJ Scopus

    Welcome to the Special Issue of Life entitled “Neutralizing-Antibody-Based Treatments for COVID-19: Achievements and Lessons Learnt for Future Pandemics” [...]

  3. Journal Article Full text

    Home and Out-of-Hospital Therapy with COVID-19 Convalescent Plasma in Europe

    Daniele Focosi; Massimo Franchini

    Life, Vol. 12 No. 11 · 2022 · English · DOAJ Scopus

    COVID19 convalescent plasma (CCP) has proven an effective treatment for outpatients, and CCP collected from vaccinated donors is among the few effective therapeutic options for immunocompromised patients. Despite this, most countries are still relying over in-hospital compassionate usages outside…

  4. Journal Article

    The changing landscape of treatment for acquired hemophilia A

    Massimo Franchini; Daniele Focosi

    Bleeding, Thrombosis and Vascular Biology, Vol. 4 No. 1 · 2025 · English · DOAJ Scopus

    Acquired hemophilia A (AHA) is a rare acquired autoimmune disorder caused by autoantibodies against coagulation factor VIII (FVIII), which cause a hemorrhagic diathesis, not rarely of severe degree. Standard treatment consists of bleeding control with bypassing agents (recombinant activated factor…

  5. Journal Article

    Emergency management of patients being treated with oral anticoagulants

    Franco Manzato; Massimo Franchini

    Italian Journal of Medicine, Vol. 7 No. 4 · 2013 · English · DOAJ Scopus

    Vitamin K antagonists (VKA) are among the most widely prescribed drugs in the industrialized world. In fact, for decades, VKA have been the only orally available anticoagulant for the primary and secondary prevention of venous and arterial thrombotic events. Their efficacy has been widely…

  6. Journal Article Full text

    The Role of Convalescent Plasma in COVID-19: A Conclusive Post-Pandemic Review

    Massimo Franchini; Daniele Focosi

    Life, Vol. 13 No. 12 · 2023 · English · DOAJ Scopus

    COVID-19 convalescent plasma (CCP) has represented the frontline response to the COVID-19 pandemic, largely because of encouraging historical evidences in previous pandemics, biological plausibility, and the initial unavailability of targeted antivirals. Unfortunately, investigator-initiated…

  7. Journal Article Full text

    Hyperimmune Plasma and Immunoglobulins against COVID-19: A Narrative Review

    Massimo Franchini; Daniele Focosi

    Life, Vol. 14 No. 2 · 2024 · English · DOAJ Scopus

    Since late 2019, the new SARS-CoV-2 virus belonging to the Coronaviridae family has been responsible for COVID-19 pandemic, a severe acute respiratory syndrome. Several antiviral therapies, mostly derived from previous epidemics, were initially repurposed to fight this not rarely life-threatening…

  8. Journal Article Full text

    What a Transfusion Physician Should Know about Monkeypox Virus: Barriers to and Risks for Transmission, and Possible Mitigation Strategies

    Daniele Focosi; Massimo Franchini

    Diagnostics, Vol. 12 No. 9 · 2022 · English · DOAJ Scopus

    The ongoing monkeypox pandemic is posing new challenges to the transfusion community. While to date most regulatory agencies recommend deferrals for cases and contacts, we summarize here arguments for introduction of universal PCR testing of MPXV in blood donations and donated tissue/organs.

  9. Journal Article

    The never ending success story of tranexamic acid in acquired bleeding

    Massimo Franchini; Pier Mannuccio Mannucci

    Haematologica, Vol. 105 No. 5 · 2020 · English · DOAJ Scopus

    Tranexamic acid (TXA) is an anti-fibrinolytic agent that acts by inhibiting plasminogen activation and fibrinolysis. Although its first clinical use dates back more than 50 years, this hemostatic agent is still the object of intense clinical and developmental research. In particular, renewed…

  10. Journal Article

    Direct oral anticoagulants and venous thromboembolism

    Massimo Franchini; Pier Mannuccio Mannucci

    European Respiratory Review, Vol. 25 No. 141 · 2016 · English · DOAJ Scopus

    Venous thromboembolism (VTE), consisting of deep vein thrombosis and pulmonary embolism, is a major clinical concern associated with significant morbidity and mortality. The cornerstone of management of VTE is anticoagulation, and traditional anticoagulants include parenteral heparins and oral…

  11. Journal Article

    Interactions between genotype and phenotype in bleeding and thrombosis

    Massimo Franchini; Pier Mannuccio Mannucci

    Haematologica, Vol. 93 No. 5 · 2008 · English · DOAJ Scopus

    The hemostatic balance is the result of an equilibrium between procoagulant and anticoagulant factors that interact with each other to ensure hemostasis at sites of vascular injury. Abnormalities of hemostatic factors due to defects in the corresponding genes can result in a tendency to hemorrhage…

  12. Journal Article

    Acquired von Willebrand syndrome: focused for hematologists

    Massimo Franchini; Pier Mannuccio Mannucci

    Haematologica, Vol. 105 No. 8 · 2020 · English · DOAJ Scopus

    The acquired von Willebrand syndrome (AvWS) is a rare bleeding disorder with laboratory findings similar to those of inherited von Willebrand disease. However, unlike the inherited disease, AvWS occurs in persons with no personal and family history of bleeding and is often associated with a variety…

  13. Journal Article Full text

    Modified Hemagglutination Tests for COVID-19 Serology in Resource-Poor Settings: Ready for Prime-Time?

    Daniele Focosi; Massimo Franchini; Fabrizio Maggi

    Vaccines, Vol. 10 No. 3 · 2022 · English · DOAJ Scopus

    During the ongoing COVID-19 pandemic, serology has suffered several manufacturing and budget bottlenecks. Kode technology exposes exogenous antigens on the surface of cells; in the case of red blood cells, modified cells are called kodecytes, making antibody–antigen reactions detectable by the…

  14. Journal Article Full text

    COVID-19 Vaccination in Patients with Hematological Malignances

    Massimo Franchini; Fabrizio Maggi; Daniele Focosi

    Vaccines, Vol. 13 No. 5 · 2025 · English · DOAJ Scopus

    Patients with hematologic malignancies (HM) represent a population particularly vulnerable to infections due to their cancer-related immune deficiency and the immunosuppressive treatment they are administered. Accordingly, a high hospitalization and mortality rate has been consistently reported in…

  15. Journal Article

    Azienda Ospedaliera "Carlo Poma", Mantova

    Francesco Frattini; Silvia Crestani; Massimo Franchini

    Mediterranean Journal of Hematology and Infectious Diseases, Vol. 1 · 2014 · English · DOAJ Scopus

    Data on the efficacy and tolerability of dasatinib in the treatment of chronic myeloid leukaemia (CML) derive from studies on extremely selected groups of patients, and so information from very elderly patients and patients with severe comorbid conditions are very scarce. This can lead to…

  16. Journal Article

    Therapy for Children with Henoch-Schonlein Purpura Nephritis: A Systematic Review

    Marco Zaffanello; Milena Brugnara; Massimo Franchini

    The Scientific World Journal, Vol. 7 · 2007 · English · DOAJ Scopus

    Although severe kidney involvement in children with Henoch-Shonlein purpura (HSP) is rarer than that in adults, morbidity should not be underevaluated and follow-up is mandatory. Some drugs are introduced as well-defined treatment options, others can be promising therapeutic alternatives.

  17. Journal Article Full text

    On the Need to Determine the Contribution of Anti-Nucleocapsid Antibodies as Potential Contributors to COVID-19 Convalescent Plasma Efficacy

    Daniele Focosi; Massimo Franchini; Arturo Casadevall

    Viruses, Vol. 14 No. 11 · 2022 · English · DOAJ Scopus

    Historically the therapeutic potential of polyclonal passive immunotherapies in viral diseases has been related to antiviral neutralizing antibodies, but there is also considerable evidence that non-neutralizing antibodies can translate into clinical benefit as well. In the setting of SARS-CoV-2…

  18. Journal Article Full text

    The Road towards Polyclonal Anti-SARS-CoV-2 Immunoglobulins (Hyperimmune Serum) for Passive Immunization in COVID-19

    Daniele Focosi; Marco Tuccori; Massimo Franchini

    Life, Vol. 11 No. 2 · 2021 · English · DOAJ Scopus

    Effective treatments specific for COVID-19 are still lacking. In the setting of passive immunotherapies based on neutralizing antibodies (nAbs), randomized controlled trials of COVID-19 convalescent plasma (CCP) anti-SARS-CoV-2 Spike protein monoclonal antibodies (mAb), which have been granted…

  19. Journal Article

    Novel evidence for a greater burden of ambient air pollution on cardiovascular disease

    Pier Mannuccio Mannucci; Sergio Harari; Massimo Franchini

    Haematologica, Vol. 104 No. 12 · 2019 · English · DOAJ Scopus

    Ambient and household air pollution is a major health problem worldwide, contributing annually to approximately seven million of all-cause avoidable deaths, shorter life expectancy, and significant direct and indirect costs for the community. Air pollution is a complex mixture of gaseous and…